|
GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
|
JPS4921149B1
(OSRAM)
|
1970-12-28 |
1974-05-30 |
|
|
|
JPS4921148B1
(OSRAM)
|
1970-12-28 |
1974-05-30 |
|
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
|
DE69120221T2
(de)
|
1990-07-03 |
1996-11-21 |
Mitsui Petrochemical Ind |
Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
|
|
AU692090B2
(en)
|
1995-04-13 |
1998-05-28 |
Taiho Pharmaceutical Co., Ltd. |
Novel 4,6-diarylpyrimidine derivatives and salts thereof
|
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
|
CN1129597C
(zh)
|
1997-07-24 |
2003-12-03 |
全药工业株式会社 |
杂环化合物和以其为有效成分的抗肿瘤剂
|
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンａ３拮抗剤
|
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
|
PT930302E
(pt)
|
1998-01-16 |
2003-07-31 |
Hoffmann La Roche |
Derivados de benzo-sulfona
|
|
WO1999065897A1
(en)
|
1998-06-19 |
1999-12-23 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
|
EP1144390A2
(en)
|
1999-01-22 |
2001-10-17 |
Amgen Inc., |
Kinase inhibitors
|
|
CA2383546A1
(en)
|
1999-06-30 |
2001-01-04 |
William H. Parsons |
Src kinase inhibitor compounds
|
|
CA2376951A1
(en)
|
1999-06-30 |
2001-01-04 |
Peter J. Sinclair |
Src kinase inhibitor compounds
|
|
US6329380B1
(en)
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
|
JP2003505384A
(ja)
|
1999-07-15 |
2003-02-12 |
ファーマコピーア，インコーポレーティッド |
ブラジキニンｂ１受容体アンタゴニスト
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
CA2400447C
(en)
|
2000-02-17 |
2008-04-22 |
Amgen Inc. |
Kinase inhibitors
|
|
JP5074653B2
(ja)
|
2000-03-29 |
2012-11-14 |
サイクラセル リミテッド |
２−置換４−ヘテロアリール−ピリミジンおよび増殖性障害におけるその使用
|
|
WO2001083456A1
(en)
|
2000-04-27 |
2001-11-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
Condensed heteroaryl derivatives
|
|
CN1657523A
(zh)
|
2000-04-28 |
2005-08-24 |
田边制药株式会社 |
环状化合物
|
|
JP2004501913A
(ja)
|
2000-06-23 |
2004-01-22 |
ブリストル−マイヤーズ スクイブ ファーマ カンパニー |
ヘテロアリール−フェニル置換Ｘａ因子阻害剤
|
|
EP1317433A2
(en)
|
2000-09-06 |
2003-06-11 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
KR20030032035A
(ko)
|
2000-09-15 |
2003-04-23 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제 억제제로서 유용한 피라졸 화합물
|
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
MXPA03005610A
(es)
|
2000-12-21 |
2003-10-06 |
Vertex Pharma |
Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
|
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
|
WO2002064096A2
(en)
|
2001-02-16 |
2002-08-22 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
|
CA2448626A1
(en)
|
2001-05-25 |
2002-12-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
EP1397142A4
(en)
|
2001-06-19 |
2004-11-03 |
Bristol Myers Squibb Co |
PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
WO2004078163A2
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
DE60332433D1
(de)
|
2002-03-15 |
2010-06-17 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
ES2289279T3
(es)
|
2002-03-15 |
2008-02-01 |
Vertex Pharmaceuticals Incorporated |
Composiciones utiles como inhibidores de proteinquinasas.
|
|
US7179826B2
(en)
|
2002-03-15 |
2007-02-20 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
AU2003218215A1
(en)
|
2002-03-15 |
2003-09-29 |
Vertex Pharmaceuticals, Inc. |
Azolylaminoazines as inhibitors of protein kinases
|
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
|
CA2499497A1
(en)
|
2002-09-27 |
2004-04-08 |
Merck & Co., Inc. |
Substituted pyrimidines
|
|
JP2006515274A
(ja)
|
2002-10-08 |
2006-05-25 |
マサチューセッツ・インスティテュート・オブ・テクノロジー |
コレステロール輸送の調節のための化合物
|
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
|
MXPA05005477A
(es)
|
2002-11-21 |
2005-07-25 |
Chiron Corp |
Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
|
|
JP2006521357A
(ja)
|
2003-03-24 |
2006-09-21 |
メルク エンド カムパニー インコーポレーテッド |
ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
AU2004230928B2
(en)
|
2003-04-09 |
2010-12-02 |
Exelixis, Inc. |
Tie-2 modulators and methods of use
|
|
US20060229308A1
(en)
|
2003-07-15 |
2006-10-12 |
Neurogen Corporation |
Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands
|
|
US7566712B2
(en)
|
2003-07-16 |
2009-07-28 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
PE20050952A1
(es)
*
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
AU2005232745A1
(en)
|
2004-04-13 |
2005-10-27 |
Astellas Pharma Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
CA2587642C
(en)
*
|
2004-11-30 |
2013-04-09 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
|
CN101080401A
(zh)
|
2004-12-13 |
2007-11-28 |
神经能质公司 |
经取代的二芳基类似物
|
|
WO2006065872A1
(en)
|
2004-12-13 |
2006-06-22 |
Neurogen Corporation |
Piperazinyl-pyridine analogues
|
|
EP1836169B9
(en)
|
2004-12-28 |
2012-07-04 |
Kinex Pharmaceuticals, LLC |
Compositions and methods of treating cell proliferation disorders
|
|
EP1838703A2
(en)
|
2005-01-19 |
2007-10-03 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
|
KR20070108916A
(ko)
|
2005-02-25 |
2007-11-13 |
쿠도스 파마슈티칼스 리미티드 |
Ｍｔｏｒ 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도
|
|
AR053712A1
(es)
|
2005-04-18 |
2007-05-16 |
Neurogen Corp |
Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
|
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
|
BRPI0706395A2
(pt)
|
2006-01-11 |
2011-03-22 |
Astrazeneca Ab |
composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
|
|
JO2660B1
(en)
*
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2007120897A2
(en)
*
|
2006-04-13 |
2007-10-25 |
The Trustees Of Columbia University In The City Of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
|
AR064571A1
(es)
|
2006-12-28 |
2009-04-08 |
Basf Ag |
Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
|
|
MX2009008341A
(es)
|
2007-02-06 |
2009-08-12 |
Novartis Ag |
Inhibidores de cinasa de pi3 y metodos para su uso.
|
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
|
CN101801962A
(zh)
|
2007-07-09 |
2010-08-11 |
阿斯利康(瑞典)有限公司 |
用于治疗增殖疾病的三取代嘧啶衍生物
|
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
|
RU2496500C2
(ru)
|
2008-03-05 |
2013-10-27 |
Новартис Аг |
Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr
|
|
MX338088B
(es)
|
2008-03-26 |
2016-04-01 |
Novartis Ag |
Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
|
|
WO2009120094A2
(en)
|
2008-03-27 |
2009-10-01 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
US8575338B2
(en)
|
2008-04-09 |
2013-11-05 |
Mitsubishi Tanabe Pharma Corporation |
Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
BRPI0921802A8
(pt)
|
2008-10-31 |
2018-03-13 |
Novartis Ag |
uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
US8513242B2
(en)
|
2008-12-12 |
2013-08-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
|
US8673891B2
(en)
|
2009-02-06 |
2014-03-18 |
Nippon Shinyaku Co., Ltd. |
Aminopyrazine derivative and medicine
|
|
CA2755394C
(en)
|
2009-03-13 |
2021-10-19 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
|
CN102438993A
(zh)
|
2009-05-19 |
2012-05-02 |
陶氏益农公司 |
用于控制真菌的化合物和方法
|
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
TWI393716B
(zh)
|
2009-08-04 |
2013-04-21 |
Merck Sharp & Dohme |
作為ｉｘａ因子抑制劑之雜環化合物
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
TWI499592B
(zh)
|
2009-09-09 |
2015-09-11 |
Avila Therapeutics Inc |
Ｐｉ３激酶抑制劑及其用途
|
|
JP5967827B2
(ja)
|
2009-12-09 |
2016-08-10 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
WO2011143160A2
(en)
|
2010-05-10 |
2011-11-17 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
WO2012009678A1
(en)
|
2010-07-16 |
2012-01-19 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their method of use
|
|
ES2699951T3
(es)
|
2010-10-01 |
2019-02-13 |
Novartis Ag |
Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina, un inhibidor PIK3
|
|
NZ734152A
(en)
|
2010-10-18 |
2019-03-29 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
BR112013020159A2
(pt)
|
2011-02-11 |
2016-11-08 |
Dana Farber Cancer Inst Inc |
método para inibir células tumorais de hamartoma
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
KR20140059786A
(ko)
|
2011-09-01 |
2014-05-16 |
노파르티스 아게 |
골암의 치료에 사용하기 위한 또는 골 내로의 원발성 암 세포의 전이성 파종을 예방하기 위한 pi3k 억제제
|
|
UA111503C2
(uk)
|
2011-09-27 |
2016-05-10 |
Новартіс Аг |
3-піримідин-4-іл-оксазолідин-2-они як інгібітори мутантної idh
|
|
CA2851082A1
(en)
|
2011-10-06 |
2013-04-11 |
Merck Sharp & Dohme Corp. |
1,3-substituted azetidine pde10 inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
MX360892B
(es)
*
|
2012-05-16 |
2018-11-20 |
Novartis Ag |
Régimen de dosificación para un inhibidor de cinasa pi-3.
|
|
MX2014014969A
(es)
|
2012-06-06 |
2015-03-13 |
Novartis Ag |
Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral.
|
|
US20150216870A1
(en)
|
2012-08-16 |
2015-08-06 |
Novartis Ag |
Combination of PI3K Inhibitor and C-Met Inhibitor
|
|
WO2014064058A1
(en)
|
2012-10-23 |
2014-05-01 |
Novartis Ag |
Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
EP2970242B1
(en)
|
2013-03-14 |
2017-09-06 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
GEP201706699B
(en)
|
2013-03-14 |
2017-07-10 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|